Using a proactive strategy helps to identify DCM patients at an earlier stage and improve their survival, especially those with mutations in high-risk genes such as LMNA, PLN, SCN5A or RBM20 [4,7,8]. This evidence concerns the gene SCN5A and familial dilated cardiomyopathy.